## Pre-emptive Analgesia for the Prevention of Chronic Postsurgical Pain: A Systematic Review and Meta-analysis with Trial Sequential Analysis

## Endale Gebreegziabher Gebremedhn<sup>1\*</sup>, Worku Mekonnen Sefefe<sup>2</sup>

<sup>1</sup>Department of Anaesthesia, University of Gondar, Ethiopia; <sup>2</sup>Department of surgery, University of Gondar, Ethiopia

**Correspondence to:** Endale Gebreegziabher Gebremedhn, Department of Anaesthesia, University of Gondar, Ethiopia, Tel: 251955220458; E-mail: gebaw21@gmail.com

## SUPPLEMENTARY MATERIAL

Study	Sample size at	Pre- emptive	Dose, route a drug given	and time	Surgery	Pain assess-	Primary outcome:	Secondary outcome
	different times	analgesia	Treatment group	Control/ active treatment group		ment	presence of postsurgic al pain at>3 months.	
Grigoras et al.	T=17 C=19	Lidocaine	B=1.5 mg/kg IV followed by INF=1.5 mg/kg IV, after ETTI and stopped 60 minutes after skin closure	Received an equivalent saline.	Breast surgery	MPQ, VAS (0- 10)	At 3 months: CPSP: lidocaine <i>vs.</i> 2 (11.8%) <i>vs.</i> control 9 (47.4%) ( <i>P</i> =0.031).	At 3 months: Worse pain during moment lidocaine VS. controls 0(0%) VS. 8 (41.2%) (P=0.003). Overall intensity of pain (mean $\pm$ SD): 0.2 $(\pm 0.5) VS.$ $0.9 (\pm 1.4)$ (P=0.023). Hyperalges ia lidocaine

Lavand'h omme et al.	T=20/20/ 20/20	Ketamine	G3=EPI- EPI: Ketamine= 0.5 mg/kg IV bolus 30 minutes before skin incision followed by epidural 0.25 mg/kg/hr till end of surgery	G1=IV-IV G2=IV- EPI G4=EPI- IV	Digestive surgery	VAS (0- 10)	6 months: Patients treated with preop bolus ketamine G1: 10 (51%), G2:2 (10%), G3:0 (0%) and G4:0 (0%) (P<0.01). 12 months: G1:6 (28%), G2: 2 (11%), G3:0 (0%) and G4:0 (0%) (P<0.05) developed pain.	<b>VS.</b> control (mean $\pm$ SD): 0.2( $\pm$ 0.8) <b>VS.</b> 3.2( $\pm$ 4.5) (P= 0.002). At 6 months: treatment group (G3) 1 (5%) <b>VS.</b> group 2: 2 (10%) and group 4: 3 (15%) patients developed back pain.
Jahangiri et al.	T=13 C=11	Epidural infusion: diamorphi ne, bupivacai ne, clonidine	INF: diamorphin e=5 mg; bupivacaine =75 mg and clonidine=1 50 µgm (24-5 hrs before surgery)	Received on demand opioids	Lower limb amputati on	VAS (0- 10)	Phantom pain at 6 months in controls 9 (72.7%) VS. study groups 3 (7.7%) (P=0.002) and 12 months in controls 8 (72.7%) VS. study groups 2 (7.7%) (P=0.002).	-
Suzuki et al.	T=22 C=22	Epidural plus Ketamine (IV) -Epidural plus saline	Ketamine=0 .05 mg/kg/hr IV infusion after ETTI on top of epidural that	Saline IV infusion on the top of epidural	Thoracot omy	NRS	3 months: Fourteen (58.3%) patients from the control group and 7 (28%)	At 3 months (n=14; P=0.56): heavy pain from the wound ketamine 6

continued patients   for 3 days from   postoperativ ketamine	(27.3%) and control
postoperativ ketamine	
	9 (40.9%)
ely group	patients.
experience	Sharp pain:
d pain	ketamine 0
$(NRS \ge 1)$	(0%) and
( <i>P</i> =0.03).	control 1
Nine	(4.5%)
(37.5%)	patients.
patients	At 6
from the	months
control	(n=12;
group and	<i>P</i> =0.4):
	heavy pain
patients	ketamine 7
from	(31.8%)
ketamine	and control
	8 (36.4%)
group received	patients.
medication	Tingling:
	ketamine 5
for pain control	(22.7%)
	· · · ·
(P=0.03).	and control
6 months:	6 (27.3%)
Sharp pain:	patients.
ketamine 0	
(0%) and	
control 3	
(13.6%)	
patients.	
SalengrosT=18Low doseLow doseHigh-doseThoracotDN4Numbers	NRS at 3
et al. C=20 remifenta remifentanil remifenta omy neuropat of patients	months
nil with IV infusion nil IV hic pain experience	(mean +
epidural (average infusion diagnost d pain	SD): High-
with 0.5% effect site (average ic (remifenta	Dose
ropivacain concentratio effect-site question nil):	Group:
e n 1.99 concentrat naire -3 months:	$3.00 \pm 1.51$
0.02 ion 5.61 high dose	and low
ng/mL) 0.84 15/20	dose: 2.43
with ng/mL) (75%) vs.	<u>+</u> 1.62
	(P=0.42).
	NRS at $6$
	months
	$(\text{mean} \pm$
(1-0.013)	(mean $\pm$ SD): high
	dose: 2.88
10/20	$\pm$ 1.36 and
anaesthesia (80%) <b>vs.</b>	low dose: $2.50 \pm 2.29$
low dose	$3.50 \pm 2.28$
5/18	(P=0.67).
(27.8%)	At 13
(27.876) (P=0.008)	months
	(mean <u>+</u>
-13 months:	SD): high dose: 2.28

							high dose 14/20 (70%) <b>vs.</b> low dose 3/18 (16.7%) (P=0.009)	$\pm 1.33$ and low dose: $4.33 \pm 2.08$ ( <i>P</i> =0.10).
Obata et al.	T=28 C=30	Thoracic epidural	4 ml of 1.5% mepivacain e bolus started 20 minutes before skin incision followed by 4 ml/hr infusion until 72 hrs after operation	4 ml of 1.5% mepivacai ne bolus started at the end of surgery followed by 4 ml/hr infusion until 72 hrs after operation	Thoracot omy	NRS	3 months: 14 (50%) and 23 (77%) patients developed long-term pain in pre-group and post group respectivel y. 6 months: In pre- group 9 (33%) and post group 20 (67%) patients developed long-term pain.	At 3 months: In pre-group 11% and in post group 23% patients took medication for pain control. 6 months: The NRS was lower in the Pre group at 6 months after operation (P=0.015). Whereas 4% and 6% patients took medication for pain control from pre and post groups respectivel y
Karanikol as et al.	T=13/13/ 13/13 C=13	Epidural/P CA	Epi/Epi/Epi : bupivacaine , 2 mg/ml, and fentanyl, 2 µg/ml, infusion at 4–8 ml/h), started before 48 hrs of surgery. PCA/Epi/E pi: IV	Received conventio nal analgesia	Limb amputati on	VAS, MPQ- PRIR	At 6 months: PLP prevalence : Epi/Epi/Ep i 1 (7.7%), PCA/Epi/E pi 4 (30.7%), PCA/Epi/P CA 7 (58.3%) and PCA/GA/P	

Comez et al.	T=20/20 C=20	-Epidural (PE)	fentanyl 25 µg; lockout, 20 min; and no basal infusion) for 48 h and also received epidural normal saline at 2 ml/h. PCA/GA/P CA: IV fentanyl 25 µg; lockout, 20 min; no basal infusion), started at 48 h before surgery. Epidural (PE): 10-15	No preoperati	Thoracot	VAS	CA 3 (23%) groups compared to the control group 9 (75%) (P=0.004). PLP VAS score: median (minimum- max): Epi/Epi/Ep i 0 (0-20), PCA/Epi/E pi 0 (0-20), PCA/Epi/E pi 0 (0-42), PCA/Epi/P CA 20 (0- 40), PCA/GA/P CA 0 (0- 30) and control 20 (0-58) (P=0.001). 6 months: The	6 months: Patient
		-Epidural + Dexketopr ofen (PED)	ml of 0.125% levobupivac aine before 5 minutes of anaesthesia. Epidural + Dexketopro fen (PED): 10-15 ml of 0.125% levobupivac aine before 5 minutes of anaesthesia. Dexketopro fen 50 mg in 100 m normal saline IV infusion before 15 minutes of skin incision.	ve analgesia was given			incidence of post thoracotom y chronic pain in PED 2 (10%), PE 4 (20%) and Control 6 (30%). The VAS score (mean $\pm$ SD) control group: 1.85 $\pm$ 1.496 VS. PE: 1.15 $\pm$ 1.348 VS. PED: 0.60 $\pm$ 1.142 (P=0.017).	satisfaction score: control 9 (45%) vs. PE 11 (55%) vs. PED 18 (90%) (P=0.008).

Kairaluo ma et al.	T=30 C=30	Paraverteb ral nerve block (PVB)	0.5% bupivacaine of 1.5 mg/kg injected at T3 before anaesthesia.	Received saline subcutane ously at the correspon ding puncture site	Breast surgery with axillary dissectio n	NRS	6 months: the prevalence of pain symptoms (tactile stimulus: median/ran ge) was lower in PVB: 0.5 (0-3) VS. sham group 1 (0- 4) (P=0.029). 12 months: prevalence of pain symptoms: control 23 (77%) VS. PVB 13 (43%) (P=0.008)	At 12 months NRS median (range): motion related pain: PVB 0 (0–6) <b>v5.</b> 2 (0–8) (P=0.003). Pain at rest: PVB 0 (0–1) <b>v5.</b> control 0 (0–8) (P=0.011).
Dertwink el et al.	T=25 C=28	Ketamine	KG=0.5 mg/kg IV bolus immediatel y after induction of anaesthesia, followed by 0.003 mg/kg/24 hr IV infusion and 0.001 mg/kg/48 hr IV infusion	Not received perioperat ive ketamine	Amputati on of limbs	NRS	9 months: KG one patient (9.1%) and control group 10 (71.4%) patients developed severe phantom limb pain (P=0.01).	9 months: Seven (63.6%) and 11 (78.5%) patients developed chronic phantom limb pain in ketamine and control groups respectivel y.
Xu et al.	T=62 C=79	Celecoxib, tramadol and acetamino phen	Celecoxib= 200 mg BID orally, tramadol 37.5 mg orally and acetaminop hen 325 mg orally TID 72-1 hr before surgery.	No drug was given to the control group preoperati vely	Total knee arthropla sty	VAS	There was low VAS score during moment at 3 months in treatment group compared to the control group (P=0.012)	-

Remerand et al.	T=72 C=70	Ketamine	B=0.5 mg/kg IV before skin incision, followed by 2 µgm/kg/min for 24 hour infusion	Saline bolus, followed by saline	Total hip arthropla sty	NRS	6 months: Ketamine group 6 (8%) and placebo group 15 (21%) patients experience d pain at rest (P=0.036).	6 months: 3 (4.2%) from ketamine group and 10 (13.3%) placebo group reported their pain NRS>3 at rest (P=0.04).
Senturk et al.	T=22 C=24/23	Thoracic epidural analgesia (TEA)	Pre-TEA: bolus of 10 ml of 0.1% bupivacaine plus 0.1 ml morphine 30 minutes before anaesthesia, followed by 7 ml/hr infusion of the same solution during operation.	In Post TEA group, no epidural medicatio n was applied until the postoperat ive period	Thoracot omy	NRS	At 6 months: Pre-TEA 10 (45%), Post-TEA 15 (63%) and IV- PCA 18 (78%) (P<0.05).	6 months: The NRS scores (mean $\pm$ SD) were Pre- TEA ( 0.6 $\pm$ 0.8), Post-TEA ( 0.9 $\pm$ 0.9) and IV- PCA ( 1.4 $\pm$ 1.2)
Khurana et al.	T=30/30 C=30	Gabapenti n, pregabalin	Gabapentin =300 mg orally and Pregabalin= 75 mg orally before 1 hr of surgery and every 8 hr for 7 days postoperativ ely	Received placebo before 1 hr of surgery	Spinal surgery	VAS	3 months: VAS score (mean) in pregabalin group was significantl y low compared with gabapentin and placebo group (P<0.05).	Prolo functional score: excellent score gabapentin 3 (10%), pregabalin 13 (43.3%) and placebo group 9 (30%) ODIS: moderate disability gabapentin 13 (43.3%), pregabalin 3 (10%) and placebo 14 (46.7%).

Buvanend ran et al.	T=113 C=115	Pregabalin	Pregabalin 300 mg	Received matched	Total knee	NRS	3 months: neuropathi	3 months: allodynia
	C=115		300 mg orally 1-2 hr before surgery	matched placebo tablet orally 1-2 hr before surgery	knee arthropla sty		neuropathi c pain in pregabalin group 0 (0%) <i>vs</i> . placebo 10 (8.7%) (P=0.001). 6 months: the incidence of neuropathi c pain in pregabalin 0 (0%) <i>vs</i> . placebo 6 (5.2%) (P=0.014).	on operated leg was low in pregabalin group 2 (2%) <i>VS.</i> placebo group 14 (12%) (P=0.002). 6 months: allodynia on operated leg was low in pregabalin group 0 (0%) <i>VS.</i> placebo group
								9(8%) (P=0.002).
Amr et al.	T=50/50 C=50	venlafaxin e	Venlafaxine =37.5 mg/day and gabapentin 300 mg/day orally the night before surgery and for 10 days postoperativ ely	Received placebo the night before surgery and for 10 days postoperat ively	mastecto my	VAS	6 months: stabbing/pr icking pain significantl y reduced in venlafaxin e group 7 (14%) compared to the control group 20 (40%) (P=0.003) and gabapentin group 16 (32%) (P=0.028). Burning pain was also significantl y reduced in venlafaxin e group 1(2%)	6 months: more patients used opioids in the control group 18 (36%) (P=0.02) and gabapentin groups 17 (34%) compared to venlafaxin e group 8 (16%) (P=0.03)).

							compared with the control group 11 (22%) (P=0.0018)	
Bouzia et al.	T=31/31 C=31	pregabalin	Group2: Pregabalin= 75 and Group3: 150 mg orally before surgery.	Group1: Placebo capsule orally before surgery	Cardiac surgery	VRS	3 months: analgesia consumpti on group1: 26/31, group2: 16/31 and group3: 10/31 (P <0.001)	3 months: VAS score: median (minimum, max): Control 3 (2, 5), group2: 2 (1, 3) and group3: 2 (1, 3) (P<0.001). sleep disturbanc e group1: 16/31, group2: 5/31 and group3: 3/31 (P <0.001).
Sen et al.	T=20/20 C=20	Ketamine and pregabalin	Ketamine group: placebo capsule, 0.3 mg/kg IV bolus and 0.05 mg/kg/hr infusion before skin incision until the end of operation. Pregabalin group=1.2 gram orally and bolus plus infusion of saline 1 hr before skin incision	Placebo capsule and bolus plus infusion of saline	hysterect omy	VRS	3 and 6- months:the incidence of incisional pain and pain scores were significantl y lower in the gabapentin group compared with the ketamine and control groups ( <i>P</i> <0.001)	

Brogly et al.	T=23 C=24	Gabapenti n	Gabapentin =1200 mg orally 2 hr before surgery	Placebo orally 2 hr before surgery	thyroidec tomy	DN2	6 months: DN2 score was significantl y reduced in gabapentin group 1 (4.3%) compared to the placebo group 7 (29.2%) (P=0.04).	-
Ju et al.	T=50/48/ 38 C=48/43/ 39	Epidural	Epidural: initiated before skin incision and maintained with 5-10 ml/hr 0.5% ropivacaine during operation	Cryo group: each intercostal nerve exposed at the end of surgery and received 90 seconds applicatio n of cold (-70 $C^0$ )	Thoracot omy	VRS	3 months: moderate to severe pain epidural 4 (8%) <i>VS</i> . cryo group 11 (22.9%) (P=0.077). 6 months: severe to moderate pain- epidural 3 (6.3%) and cryo group 12 (27.9%) (P=0.013) 12 months: moderate to severe pain epidural 2 (5.3%) <i>VS</i> . cryo group 9 (23.1%) (P=0.056).	Allodynia like pain: 6 months: epidural 1(2.1%) and cryo 6 (16.3%) (P=0.044). 12 months: epidural 0 (0%) and cryo 6 (15.4%) (P=0.025). Interferenc e with daily life: 3 months: epidural 6 (12%) and cryo 18 (37.5%) (P=0.003). 6 months: epidural 5 (10.4%) and cryo 15 $(34.9\%)$ (P=0.005). 12 months: epidural 3 (7.9%) and cryo 13 (33.3%) (P=0.014).
Sen et al.	T=30 C=29	in	Gabapentin 1.2 gm orally 1 hr before surgery	A placebo capsule was taken orally 1 hr before surgery	Herniorr haphy	VAS	3 and 6 months: the mean VAS score was lower in	-

Fassoulak i et al.	T=22/20 C=22/21	Gabapen tin	Gabapentin 400 mg orally starting the night before the day of surgery and 8 days postoperativel y	Placebo capsules orally starting the night before the day of surgery and 8 days postoperat ively	Breast surgery	VAS	gabapentin (1.25) group compared with the placebo group (2.5) (P< 0.05). 3 months: 18/22 (82%) patients in control group and 10/22 (45%) patients in the treatment group developed chronic	3 months: Axillary pain 10 (22%) patient from control and 3 (14%) patients from treatment group (P=0.045). Arm pain
		-	400 mg orally starting the night before the day of surgery and 8 days postoperativel	capsules orally starting the night before the day of surgery and 8 days postoperat		VAS	group (2.5) (P< 0.05). 3 months: 18/22 (82%) patients in control group and 10/22 (45%) patients in the treatment group developed	Axillary pain 10 (22%) patient from control and 3 (14%) patients from treatment group
								groups needed analgesia (P=0.107).

Wilson et	T=15/15/	Endural	Enidural	Enidural	Lower	VAS,	3 months:	Anviato
al.	1=15/15/ 14	Epidural	Epidural: bupivacaine	Epidural bupivacai	Lower limb	VAS, MPQ,	3 months: Phantom	Anxiety significantl
al.	C=19/16/	Vatamin	0.5% of 1					-
	15 C=19/16/	Ketamin		ne 0.5% of 1	amputati	NPS, HADS	pain in ketamine	y decreased
	15	e	mg/kg with 0.5 mg/kg		on	TIADS	group 6/15	in
			ketamine	mg/kg with				ketamine
			bolus before				(40%) and	
				saline was			control	group
			starting	given before			group $7/19$	compared
			surgery.				(37%)(P=0)	with the
				starting			.867).	preoperativ
				surgery			Stump pain	e value till
							ketamine	year one $(\mathbf{D} < 0.001)$
							group 5/15	(P< 0.001)
							(33%) and	whereas
							saline	there was
							group 9/19	no
							(43%)	difference
							(P=0.635).	b/n the
							6 months:	preoperativ
							Phantom	e and
							pain Isotomino	postoperati
							ketamine	ve anxiety value till
							6/15 (40%)	
							and saline $\frac{2}{16}$	year one in saline
							3/16 (19%)	
							(P=0.252).	group $(\mathbf{P} = 0.071)$
							Stump pain ketamine	(P=0.071).
							7/15 (43%)	Depression level
							and saline	
								remarkably reduced in
							group $5/16$	ketamine
							(32%)	
							(P=0.609). 12 months:	group at 3, 6 and 12
							Phantom	months
							pain	compared
							ketamine	to placebo
							group 7/14	-
								(P-0.003)
							(50%) and saline 6/15	(P=0.003).
							(50%)	
							(J0%) (P=0.867).	
							(r =0.807). Stump pain	
							ketamine	
							3/14 (21%)	
							and saline	
							5/15 (33%)	
							(P=0.682).	
							(1 = 0.082). Median	
							NPS score	
							decreased	
							at all times	
							postoperati	
							vely in	
							both	
							groups.	
							5roups.	

Katz et al.	T=36 C=36/38	Ketamin e	Group 1: Fentanyl=1 µgm/kg IV bolus and 25 µgm/kg/hr infusion 5 minutes before induction of anaesthesia Ketamine: 0.2 mg/kg IV	Groups 2 and 3: IV fentanyl and saline (bolus plus infusion) before incision (equivalen t amount with	Radical prostatec tomy	MPQ,V AS, FUPQ	6 months: Most intense pain after surgery (VRS: mean $\pm$ SD): G1 (5.1 $\pm$ 1.9), G2 (5.6 $\pm$ 2.2) and G3 (5.1 $\pm$	-
Nikolaisa	T-17/16/	Enidural	bolus, followed by 2.5 µgm/kg/hr infusion 10 minutes before skin incision.	group 1)	Lower	VAS	2.5). VAS-rest pain G1 $(2.3 \pm 1.2)$ , G2 $(2.8 \pm 1.1)$ and G3 $(3.4 \pm 3.0)$ respectivel y.	Phantom
Nikolajse n et al.	T=17/16/ 12 C=20/20/ 16	Epidural (morphi ne and bupivaca ine)	Epidural: 0.2 mg morphine and bupivacaine 0.5% of 5-10 ml bolus were given 18 hr before amputation and continued till end of surgery	Epidural: saline and morphine 5-20 mg orally or intramusc ularly six times daily before surgery	Lower- limb amputati on	VAS	Phantom pain 3 months: block 14/17 (82%) <i>vs.</i> control 10/20 (50%) (P=0.09). 6 months: block 13/16 (81%) <i>vs.</i> control 11/20 (55%) (P=0.2). 12 months: block 9/12 (75%) <i>vs.</i> control 11/16 (69%) (P=1.0).	Phantom pain: 3 months: Block <i>VS.</i> control (82% <i>VS.</i> 50%) 6 months: Block <i>VS.</i> control (81% <i>VS.</i> 55%) 12 months: Block <i>VS.</i> control (75% <i>VS.</i> 69%)
Dualé et al.	T=34 C=35	Ketamin e	B=1 mg/kg IV before surgery, INF=1 mg/kg/hr during surgery and 1 mg/kg/24 IV	Saline during induction, operation and for 24 hrs	Thoracot omy	VAS	4 months: Ongoing pain (NPSI)=ke tamine 8 (23.5%) VS. placebo 12	4 months: Ongoing pain (PNSI) (mean <u>+</u> SD): ketamine group 8

Joseph et	T=16	Ketamin	after surgery B=0.5 mg/kg	IV	Thoracot	NRS	(34.3%) (P=0.325). 3 months:	(23.5) and placebo group 12 (34.3) (P=0.325). Evoked pain (NPSI)=ke tamine 13 (38.2%) <i>VS.</i> placebo 16 (45.7%) (P=0.529). Neuropathi c pain score (>0): ketamine 16 (47.1%) <i>VS.</i> placebo 24 (68.6%) (P=0.070). 3 months:
al.	C=19	e	B=0.3 mg/kg at induction INF=3 μgm/kg/min during operation and 1.5 μgm/kg/min for 48 h after operation	lv placebo (a saline solution under the same infusion modalities ).	omy	NKS	NRS at rest (mean $\pm$ SD): ketamine group: 1.1 $\pm$ 2.1 and control group: 0.3 $\pm$ 0.7 (P=0.385).	NRS during abduction (mean $\pm$ SD): ketamine group: 1.3 $\pm$ 2.3 and control group: 1.1 $\pm$ 2.5 (P=0.589).
Can et al.	T=20 C=20/20	Epidural	Pre-group: 10–15 mL of 0.1% levobupivacai ne epidural was given before anaesthesia. Post incision group: remifentanil 0.25–0.50 g/kg/hr infusion started 10 minutes after incision	Control group: no epidural analgesia received before and during operation	Thoracot omy	VAS	3 months: VAS score $(\geq 3)$ : control 4 (20%), post- incision group 4 (20%) and pre-group 3 $(15\%)$ (P=0.896). 6 months: VAS score $(\geq 3)$ : control 6	3 months: VAS score (mean $\pm$ SD): Control group (1.90 $\pm$ 0.96), Group post- incision (1.80 $\pm$ 1.00) and Pre- emptive group (1.65 $\pm$

							(30%), post- incision group 5 (25%) and pre-group 4 (20%) (P=0.769)	0.87) (P=0.664). 6 months: VAS score (mean $\pm$ SD): control group (2.10 $\pm$ 0.96), Group post- incision (1.95 $\pm$ 0.99) and Pre- emptive group (1.70 $\pm$ 0.92) (P=0.348).
Ryu et al.	T=65 C=68	Ketamin e added to epidural	G1: 100 mg ketamine and 2 µg/mL fentanyl were given in combination epidural levobupivacai ne before surgery	G2: 2 µg/mL of fentanyl was given in combinati on with epidural levobupiv acaine before surgery	Thoracot omy	VAS	3 months: Pain at rest ketamine group 33/65 (51%) and control group 29/68 (43%) (P=0.348).	3 months: pain with movement (coughing) ketamine group 44/65 (68%) and control group 50/68 (74%)(P=0 .46).
Hayes et al.	T=15 C=17	Ketamin e	Ketamine group: 0.5 mg/kg IV bolus before anaesthesia, followed by 0.15 mg/kg/hr for 72 hrs after operation	Control group: placebo preoperati vely, followed by saline infusion for 72 hrs after operation	Below knee amputati on		6 months: phantom pain ketamine group 7 (47%) <i>vs.</i> control 7 (71%) (P=0.28) and stump pain ketamine group 7 (47%) <i>vs.</i> control 6 (35%) (P=0.72).	